Skip to menu Skip to content Skip to footer

2025

Journal Article

Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction

Giri, Rabina, Lee, Minyi, Magor, Graham, Bergot, Anne-Sophie, He, Yaowu, Kryza, Thomas, Khan, Tashbib, Schreiber, Veronika, Gordon, Robert J., Zagani, Rachid, Hasnain, Sumaira Z., Lourie, Rohan, Ewing, Adam, Hooper, John D., Thomas, Ranjeny, Florin, Timothy H., Perkins, Andrew, Gala, Manish and Begun, Jakob (2025). Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction. Cellular and Molecular Gastroenterology and Hepatology 101659, 101659. doi: 10.1016/j.jcmgh.2025.101659

Pathogenic OTUD3 mutations predispose to ulcerative colitis due to barrier dysfunction

2025

Journal Article

Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations

Tan, Wei-Lian, Khoo, Emi, Khaing, Myat-Myat, Barr, Emily, Fernandes, Richard G., Pham, Hai, An, Yoon-Kyo and Begun, Jakob (2025). Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations. Journal of Gastroenterology and Hepatology, 40 (10), 2472-2481. doi: 10.1111/jgh.70019

Point-of-care intestinal ultrasound impacts inflammatory bowel disease care and reduces the need for additional investigations

2025

Journal Article

Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy

Cai, Benjamin, Giri, Rabina, Cameron, Amy J., Rahman, M. Arifur, Small, Annabelle, Altmann, Christopher, Lim, Yenkai, Rehaume, Linda M., Morrison, Mark, Wechalekar, Mihir D., Begun, Jakob, Bergot, Anne-Sophie and Thomas, Ranjeny (2025). Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy. JCI Insight, 10 (17) e188028. doi: 10.1172/jci.insight.188028

Pro-inflammatory macrophages transporting gut-derived bacterial DNA drive autoimmune arthritis in spondyloarthropathy

2025

Journal Article

IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia

Mahadevan, Uma, Jairath, Vipul, Begun, Jakob, Pudipeddi, Aviv, Garg, Mayur, De Cruz, Peter, Li Wai Suen, Christopher F. D., Choy, Matthew C., Con, Danny, Vaughan, Rose, Chetwood, John D., Clark, David A., Haifer, Craig, Sparrow, Miles P., Leong, Rupert and Mountifield, Réme (2025). IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia. Journal of Gastroenterology and Hepatology, 40 (S3), 3-22. doi: 10.1111/jgh.70020

IBD 2024: charting a new course in IBD Proceedings of the Takeda Symposium 22–23 November 2024 W Hotel, Brisbane, Queensland, Australia

2025

Journal Article

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

Gilmore, Robert, Fernandes, Richard, Hartley, Imogen, Arzivian, Arteen, Leong, Rupert, Andrew, Bridgette, Vasudevan, Abhinav, Greeve, Tessa, Moore, Gregory Thomas, Kim, Steven, Lightowler, Daniel, Singh, Abhey, Mahy, Gillian, Mithanthaya, Aditya, Venugopaul, Kannan, Han, Sangwoo, Bryant, Robert, West, Jack, Segal, Jonathan, Christensen, Britt, Corte, Crispin, Ding, Nik, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study. Intestinal Research, 23 (3), 347-357. doi: 10.5217/ir.2024.00127

Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study

2025

Journal Article

Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC

Li Wai Suen, Christopher F.D., Choy, Matthew C., Con, Danny, Cheng, Kaylene, Nigro, Julie, Breheney, Kerry, Boyd, Kristy, Pena, Raquel, Burrell, Kathryn, Rosella, Ourania, Proud, David, Brouwer, Richard, Gorelik, Alexandra, Liew, Danny, Connell, William, Wright, Emily K., Taylor, Kirstin, Pudipeddi, Aviv, Sawers, Michelle, Christensen, Britt, Ng, Watson., Begun, Jakob, Radford-Smith, Graham L., Garg, Mayur, Martin, Neal, van Langenberg, Daniel R., Ding, Nik S., Beswick, Lauren, Leong, Rupert W. ... De Cruz, Peter (2025). Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC. Gastroenterology. doi: 10.1053/j.gastro.2025.07.020

Early infliximab levels and clearance predict outcomes after infliximab rescue in acute severe ulcerative colitis: Results from PREDICT-UC

2025

Journal Article

Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading

Mathias, Ryan M., Goodsall, Thomas M., Parker, Claire E., Day, Alice S., An, Yoon K., Baraty, Brandon, Basnayake, Chamara, Begun, Jakob, Boyapati, Ray K., Burgell, Rebecca, Dolinger, Michael T., Maconi, Giovanni, Novak, Kerri L., Sagami, Shintaro, Smith, Rebecca L., Srinivasan, Ashish R., Taylor, Stuart A., Jairath, Vipul, Ma, Christopher and Bryant, Robert V. (2025). Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading. Alimentary Pharmacology and Therapeutics, 62 (8), 799-808. doi: 10.1111/apt.70250

Expert position statement: defining the role of intestinal ultrasound in assessing constipation and faecal loading

2025

Journal Article

Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

Gilmore, Robert, Murali, Amrutha, Etchegaray, Amirah, Swe, Ei, An, Yoon-Kyo and Begun, Jakob (2025). Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease. Intestinal Research, 23 (4), 475-482. doi: 10.5217/ir.2024.00174

Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn’s disease

2025

Conference Publication

Patterns And Predictors Of Steroid Use In People With Ibd In Routine Care Across ANZ

Rivas, Consuelo, Su, Wai Kin, Wilson, William E., Ng, Watson, Ghaly, Simon, Walker, Gareth, Forbes, Angela J., Su, Heidi, Schultz, Michael, Lawrance, Ian C., Dutt, Shoma, Brett, Laurel, Begun, Jakob, Lynch, Kate D., Andrews, Jane M. and Connor, Susan J. (2025). Patterns And Predictors Of Steroid Use In People With Ibd In Routine Care Across ANZ. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)03886-7

Patterns And Predictors Of Steroid Use In People With Ibd In Routine Care Across ANZ

2025

Conference Publication

Correlation Of Biochemical, Endoscopic And Histologic Endpoints In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Correlation Of Biochemical, Endoscopic And Histologic Endpoints In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)03004-5

Correlation Of Biochemical, Endoscopic And Histologic Endpoints In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial

2025

Conference Publication

Extensive Disease Clearance As A Novel Composite Endpoint To Predict Long-term Relapse In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial

Pudipeddi, Aviv, Paramsothy, Sudarshan, Kariyawasam, Viraj C., Paramsothy, Ramesh, Ghaly, Simon, Haifer, Craig, An, Yoon-Kyo, Begun, Jakob, Connor, Susan J., Corte, Crispin, Ward, Mark, De Cruz, Peter, Fung, Caroline L., Redmond, Diane, Chan, Pak Wo, Mourad, Fadi H., Kermeen, Melissa and Leong, Rupert (2025). Extensive Disease Clearance As A Novel Composite Endpoint To Predict Long-term Relapse In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)02960-9

Extensive Disease Clearance As A Novel Composite Endpoint To Predict Long-term Relapse In Vedolizumab-treated Patients With Ulcerative Colitis: A Post-hoc Analysis From The Views Randomised Controlled Trial

2025

Conference Publication

Comparative Accuracy And Reliability Of Handheld Versus Cart-based Ultrasound In Assessing Inflammatory Bowel Disease Activity

Khaing, Myat Myat, Fernandes, Richard G., An, Yoon-Kyo, Baraty, Brandon, Bryant, Robert V., Ghaly, Simon, Smith, Rebecca, Srinivasan, Ashish, Hay, Karen and Begun, Jakob (2025). Comparative Accuracy And Reliability Of Handheld Versus Cart-based Ultrasound In Assessing Inflammatory Bowel Disease Activity. Digestive Disease Week (DDW) 2025, San Diego, CA United States, 3-6 August 2025. Philadelphia, PA United States: Elsevier. doi: 10.1016/s0016-5085(25)03008-2

Comparative Accuracy And Reliability Of Handheld Versus Cart-based Ultrasound In Assessing Inflammatory Bowel Disease Activity

2025

Journal Article

Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis

Cui, Cedric S., Lerskiatiphanich, Titaya, Li, Xaria X., Giri, Rabina, Liu, Ning, Kumar, Vinod, Whittaker, Andrew K., Han, Felicity Y., Clark, Richard J., Begun, Jakob, Lee, John D. and Woodruff, Trent M. (2025). Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis. British Journal of Pharmacology, 182 (16), 3852-3869. doi: 10.1111/bph.70056

Colon‐targeted complement C5a1 receptor inhibition using pH‐sensitive nanoparticles ameliorates experimental colitis

2025

Journal Article

The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring

Gilmore, Robert, Fernandes, Richard, Schildkraut, Tamar, Joshi, Riddhi, Lin, Lyman, Vorgin, Sara, Etchegaray, Amirah, Shanmuga Anandan, Aathavan, Tambakis, George, Loebenstein, Moshe, An, Yoon-Kyo, Begun, Jakob and Wright, Emily K (2025). The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring. Crohn's and Colitis 360, 7 (2) otaf028, 1-9. doi: 10.1093/crocol/otaf028

The durability of anti-TNF therapy for Crohn’s Disease is higher in anti-TNF naïve patients and increases with proactive therapeutic drug monitoring

2025

Journal Article

SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome

Tillett, Bree J., Dwiyanto, Jacky, Secombe, Kate R., George, Thomas, Zhang, Vivian, Anderson, Dovile, Duggan, Emily, Giri, Rabina, Loo, Dorothy, Stoll, Thomas, Morrison, Mark, Begun, Jakob, Hill, Michelle M., Gurzov, Esteban N., Bell, Kirstine J., Saad, Sonia, Barlow, Christopher K., Creek, Darren J., Chong, Chun Wie, Mariño, Eliana and Hamilton-Williams, Emma E. (2025). SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome. Nature Communications, 16 (1) 2893, 1-20. doi: 10.1038/s41467-025-58319-y

SCFA biotherapy delays diabetes in humanized gnotobiotic mice by remodeling mucosal homeostasis and metabolome

2025

Conference Publication

Comparative accuracy and reliability of handheld versus cart-based ultrasound in assessing inflammatory bowel disease activity

Khaing, M. M., Fernandes, R. G., An, Y. K., Baraty, B., Bryant, R., Ghaly, S., Smith, R. L., Srinivasan, A., Hay, K. and Begun, J. (2025). Comparative accuracy and reliability of handheld versus cart-based ultrasound in assessing inflammatory bowel disease activity. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0834

Comparative accuracy and reliability of handheld versus cart-based ultrasound in assessing inflammatory bowel disease activity

2025

Journal Article

Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations

Moniruzzaman, Md, Wong, Kuan Yau, Janjua, Taskeen Iqbal, Martin, Jennifer H., Begun, Jakob and Popat, Amirali (2025). Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations. ACS Pharmacology and Translational Science, 8 (2), 543-556. doi: 10.1021/acsptsci.4c00644

Cannabidiol targets colorectal cancer cells via cannabinoid receptor 2, independent of common mutations

2025

Journal Article

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition

Akyüz, Filiz, An, Yoon Kyo, Begun, Jakob, Aniwan, Satimai, Bui, Huu Hoang, Chan, Webber, Choi, Chang Hwan, Chopdat, Nazeer, Connor, Susan J, Desai, Devendra, Flanagan, Emma, Kobayashi, Taku, Lai, Allen Yu-Hung, Leong, Rupert W, Leow, Alex Hwong-Ruey, Leung, Wai Keung, Limsrivilai, Julajak, Muzellina, Virly Nanda, Peddi, Kiran, Ran, Zhihua, Wei, Shu Chen, Sollano, Jose, Teo, Michelle Mui Hian, Wu, Kaichun, Ye, Byong Duk and Ooi, Choon Jin (2025). Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition. Intestinal Research, 23 (1), 37-55. doi: 10.5217/ir.2024.00089

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition

2025

Conference Publication

P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor

Moniruzzaman, M., Janjua, T., Begun, J. and Popat, A. (2025). P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0286

P0112 Cannabidiol (CBD) targeting of colorectal cancer cells is mutation-independent and via CB2 receptor

2025

Conference Publication

Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial

Pudipeddi, A., Dhanji, P., Paramsothy, S., Kariyawasam, V., Paramsothy, R., Ghaly, S., Haifer, C., An, Y. K., Begun, J., Connor, S., Corte, C., Ward, M., De Cruz, P., Fung, C., Redmond, D., Chan, W., Mourad, F., Kermeen, M. and Leong, R. (2025). Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial. 20th Congress of ECCO, Berlin, Germany, 19-22 February 2025. Oxford, United Kingdom: Oxford University Press. doi: 10.1093/ecco-jcc/jjae190.0431

Correlation of biochemical, endoscopic and histologic endpoints in vedolizumab-treated patients with ulcerative colitis: a post-hoc analysis from the VIEWS randomised controlled trial